Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension
- PMID: 16361357
- DOI: 10.1152/ajplung.00206.2005
Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension
Abstract
Heterozygous mutations in the type II receptor for bone morphogenetic protein (BMPR-II) and dysfunction of BMPR-II have been implicated in patients with primary pulmonary hypertension (PH). To clarify the possible involvement of BMP and BMPR-II in the development of hypoxic PH, the expression of BMP-2, BMPR-II, and their downstream signals were investigated in rat lung under normal and hypoxic conditions by RT-PCR, immunoblot, and immunohistochemical methods. In rats under normal conditions, BMP-2 is localized in the endothelium of the pulmonary artery, whereas BMPR-II is abundantly expressed in the endothelium, smooth muscle cells, and adventitial fibroblasts. After 0.5 and 3 days of exposure to hypoxia, upregulation of BMP-2 was observed in the intrapulmonary arteries. The change was accompanied by activation of its downstream signaling, p38 MAPK, and Erk1/2 MAPK, and the apoptotic process, measured by caspase-3 activity and TdT-mediated dUTP nick end labeling-positive cells. In contrast, a significant decrease in the expression of BMPR-II and inactivation of p38 MAPK and caspase-3 were observed in the pulmonary vasculature after 7-21 days of hypoxia exposure. Because BMP-2 is known to inhibit proliferation of vascular smooth muscle cells and promote cellular apoptosis, disruption of BMP signaling pathway through downregulation of BMPR-II in chronic hypoxia may result in pulmonary vascular remodeling due to the failure of critical antiproliferative/differentiation programs in the pulmonary vasculature. These results suggest abrogation of BMP signaling may be a common molecular pathogenesis in the development of PH with various pathophysiological events, including primary and hypoxic PH.
Similar articles
-
Differential effects of TGF-beta1 and BMP-4 on the hypoxic induction of cyclooxygenase-2 in human pulmonary artery smooth muscle cells.Am J Physiol Lung Cell Mol Physiol. 2004 Nov;287(5):L919-27. doi: 10.1152/ajplung.00012.2004. Epub 2004 Jun 25. Am J Physiol Lung Cell Mol Physiol. 2004. PMID: 15220111
-
Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.Circulation. 2009 Feb 3;119(4):566-76. doi: 10.1161/CIRCULATIONAHA.108.821504. Epub 2009 Jan 19. Circulation. 2009. PMID: 19153267
-
Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension.Hypertens Res. 2010 May;33(5):435-45. doi: 10.1038/hr.2010.16. Epub 2010 Feb 26. Hypertens Res. 2010. PMID: 20186146
-
The transforming growth factor-β-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease.Exp Physiol. 2013 Aug;98(8):1262-6. doi: 10.1113/expphysiol.2012.069104. Epub 2013 May 3. Exp Physiol. 2013. PMID: 23645549 Review.
-
Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?Proc Am Thorac Soc. 2006 Nov;3(8):680-6. doi: 10.1513/pats.200605-118SF. Proc Am Thorac Soc. 2006. PMID: 17065373 Review.
Cited by
-
Hypoxia inducible factor-1-dependent up-regulation of BMP4 mediates hypoxia-induced increase of TRPC expression in PASMCs.Cardiovasc Res. 2015 Jul 1;107(1):108-18. doi: 10.1093/cvr/cvv122. Epub 2015 Mar 30. Cardiovasc Res. 2015. PMID: 25824146 Free PMC article.
-
Emerging translational approaches to target STAT3 signalling and its impact on vascular disease.Cardiovasc Res. 2015 Jun 1;106(3):365-74. doi: 10.1093/cvr/cvv103. Epub 2015 Mar 17. Cardiovasc Res. 2015. PMID: 25784694 Free PMC article. Review.
-
Sanguinarine Reverses Pulmonary Vascular Remolding of Hypoxia-Induced PH via Survivin/HIF1α-Attenuating Kv Channels.Front Pharmacol. 2021 Dec 24;12:768513. doi: 10.3389/fphar.2021.768513. eCollection 2021. Front Pharmacol. 2021. PMID: 35002707 Free PMC article.
-
Metabolic reprogramming, oxidative stress, and pulmonary hypertension.Redox Biol. 2023 Aug;64:102797. doi: 10.1016/j.redox.2023.102797. Epub 2023 Jun 24. Redox Biol. 2023. PMID: 37392518 Free PMC article. Review.
-
Leukotrienes in pulmonary arterial hypertension.Immunol Res. 2014 May;58(2-3):387-93. doi: 10.1007/s12026-014-8492-5. Immunol Res. 2014. PMID: 24570092 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous